Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
argenx SE ARGX
$401.50
-$5.28 (-1.32%)
На 18:00, 12 мая 2023
-2.28%
Потенциал через год
Ключевые показатели
-
Marketcap
22485600685.00000000
-
week52high
407.93
-
week52low
281.65
-
Revenue
410746000
-
P/E TTM
-32
-
Beta
0.46183200
-
EPS
-13.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 04:00
Описание компании
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 26 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 29 июл 2022 г. |
| Morgan Stanley | Overweight | Overweight | 29 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 29 июл 2022 г. |
| Baird | Neutral | Outperform | 29 июл 2022 г. |
| Wells Fargo | Overweight | Overweight | 18 окт 2022 г. |
| Oppenheimer | Perform | 12 окт 2022 г. | |
| Truist Securities | Buy | Buy | 28 окт 2022 г. |
| SVB Leerink | Outperform | Outperform | 28 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 28 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 окт 2022 г. |
| William Blair | Outperform | 07 дек 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 10 янв 2023 г. |
| Stifel | Buy | Buy | 22 дек 2022 г. |
| Cowen & Co. | Outperform | Outperform | 25 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
All You Need to Know About argenex SE (ARGX) Rating Upgrade to Buy
Zacks Investment Research
09 мая 2023 г. в 13:45
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
argenx SE (ARGX) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 17:57
argenx SE (NASDAQ:ARGX ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Derek Archila - Wells Fargo Tazeen Ahmad - Bank of America Rajan Sharma - Goldman Sachs Yatin Suneja - Guggenheim Akash Tewari - Jefferies Thomas Smith - SVB Security Danielle Brill - Raymond James Joel Beatty - Baird Alex Thompson - Stifel Allison Bratzel - Piper Sandler Yaron Werber - Cowen Samantha Semenkow - Citi Myles Minter - William Blair Niall Alexander - Deutsche Bank Suzanne van Voorthuizen - Kempen & Company Trevor Allred - Oppenheimer Douglas Tsao - HCW Joon Lee - Truist Securities Charles Pitman - Barclays Simon Baker - Redburn Operator Good morning. My name is Rob, and I will be your conference operator today.
argenx to Present at BofA Securities 2023 Health Care Conference
GlobeNewsWire
02 мая 2023 г. в 01:00
May 2 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV.
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
GlobeNewsWire
27 апр 2023 г. в 01:00
April 27 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2023 financial results and provide a business update.
7 Biotech Stocks That Could Cure Your Portfolio Woes
InvestorPlace
19 апр 2023 г. в 19:22
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).